VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  • Bates S
  • Greer I
  • Middeldorp S
 et al. 
  • 2

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

BACKGROUND: The use of anticoagulant therapy during pregnancy is challenging because of the potential for both fetal and maternal complications. This guideline focuses on the management of VTE and thrombophilia as well as the use of antithrombotic agents during pregnancy. METHODS: The methods of this guideline follow the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. RESULTS: We recommend low-molecular-weight heparin for the prevention and treatment of VTE in pregnant women instead of unfractionated heparin (Grade 1B). For pregnant women with acute VTE, we suggest that anticoagulants be continued for at least 6 weeks postpartum (for a minimum duration of therapy of 3 months) compared with shorter durations of treatment (Grade 2C). For women who fulfill the laboratory criteria for antiphospholipid antibody (APLA) syndrome and meet the clinical APLA criteria based on a history of three or more pregnancy losses, we recommend antepartum administration of prophylactic or intermediate-dose unfractionated heparin or prophylactic low-molecular-weight heparin combined with low-dose aspirin (75-100 mg/d) over no treatment (Grade 1B). For women with inherited thrombophilia and a history of pregnancy complications, we suggest not to use antithrombotic prophylaxis (Grade 2C). For women with two or more miscarriages but without APLA or thrombophilia, we recommend against antithrombotic prophylaxis (Grade 1B). CONCLUSIONS: Most recommendations in this guideline are based on observational studies and extrapolation from other populations. There is an urgent need for appropriately designed studies in this population.

Author-supplied keywords

  • Abortion
  • Anticoagulants
  • Anticoagulants: adverse effects
  • Anticoagulants: therapeutic use
  • Antiphospholipid Syndrome
  • Antiphospholipid Syndrome: blood
  • Antiphospholipid Syndrome: complications
  • Antiphospholipid Syndrome: drug therapy
  • Cardiovascular
  • Cardiovascular: drug ther
  • Cardiovascular: preventio
  • Dose-Response Relationship
  • Drug
  • Evidence-Based Medicine
  • Female
  • Fibrinolytic Agents
  • Fibrinolytic Agents: adverse effects
  • Fibrinolytic Agents: therapeutic use
  • Heparin
  • Heparin: adverse effects
  • Heparin: therapeutic use
  • Humans
  • Low-Molecular-Weight
  • Low-Molecular-Weight: adverse effects
  • Low-Molecular-Weight: therapeutic use
  • Medical
  • Pregnancy
  • Pregnancy Complications
  • Recurrence
  • Recurrence: prevention & control
  • Risk Factors
  • Societies
  • Spontaneous
  • Spontaneous: blood
  • Spontaneous: prevention & control
  • Thrombophilia
  • Thrombophilia: drug therapy
  • Venous Thromboembolism
  • Venous Thromboembolism: drug therapy
  • Venous Thromboembolism: prevention & control

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Shannon M Bates

  • Ian Greer

  • Saskia Middeldorp

  • David L Veenstra

  • Anne-Marie Prabulos

  • Per Olav Vandvik

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free